System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Stephen J Freedland is an expert in Urology at Cedars-Sinai Medical Center (United States). As of October 2026, ScienceLeadR ranks Stephen J Freedland in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Obesity. Stephen J Freedland has authored 1,310 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 2 of them ongoing. SLR score: 5,512 (community average: 125). How the SLR is computed.

LeadR Profile

Stephen J Freedland Cedars-Sinai Medical Center United States
5 512 ScienceLeadR Reputation 5512

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

Cedars-Sinai Medical Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1310

Citations

Citations: 41 690 1st author: 216 Last author: 527 Unique author: 19

Main journals

J Urol 343
J Clin Oncol 115
Prostate Cancer Prostatic Dis 99
Eur Urol 75
Urology 60

Best Journals

J Clin Oncol 68
Ann Oncol 14
JAMA 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Variation in quality of physician communication in prostate cancer consultations.
PMID 42816534 — oncologists, communication, neoplasms, prostate, urologists, physicians, prostatic neoplasms, therapeutics, names		Prostate Cancer Prostatic Dis20260
Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial.
PMID 42671204 — neoplasms, prostate, biopsy, prostatic neoplasms, dutasteride		Prostate20260
How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data.
PMID 42572469 — androgens, neoplasms, prostate, prostate-specific antigen, veterans, prostatic neoplasms, castration, therapeutics, veterans health		Cancer20260
Local growth hormone promotes benign prostatic hyperplasia.
PMID 42518286 — cells, growth, biomedical research, aging, prostate, hormones, prostatic hyperplasia, hyperplasia, tissues, growth hormone		JCI Insight20260
Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019.
PMID 42431754 — urology, neoplasms, prostate, prostatic neoplasms		Eur Urol20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

N/A 6
Phase 2 3
Phase 3 2
Phase 4 1

By status:

Completed 6
Recruiting 2
Active not recruiting 1
Enrolling by invitation 1
Terminated 1
Withdrawn 1

By type:

Interventional 9
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 4
multicentric5to9 1
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Placebo Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy URO PRO Trial
NCT06022822 — blood, neoplasms, adenocarcinoma, prostate, biopsy, capsules, prostatic neoplasms, specimen handling, prostatectomy, men		Phase 2Recruiting2024
Intermittent Fasting Using a Fasting Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
NCT05832086 — exercise, cancer survivors, fasting, neoplasms, adenocarcinoma, prostate, diet, prostatic neoplasms, therapeutics, resistance training, intermittent fasting		Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS